Skip to search formSkip to main contentSkip to account menu

bimagrumab

A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antibodies, BlockingMonoclonal Antibodies

Narrower (1)

BYM338
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
STUDIO DEGLI EFFETTI DEL BIMAGRUMAB NELLA MIOSITE CON CORPI INCLUSI
2016
2016
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?
Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by… 
2015
2015
SP0106 Myositis: In Search of the Right Treatment
The idiopathic inflammatory myopathies (IIM) in adults are a heterogenic group of disorders characterized by muscle inflammation… 
Review
2014
Review
2014
What Does FDAʼs ‘Breakthrough’ Pathway Mean for Neurology?
There are already direct-to-consumer companies that have genetic counselors available, Goldman said. Even then, for many of these… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)